Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 16 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
CELPHARMA from Elsene, company number BE1025475981, closed financial year 2025 with a result of € 242,673 after tax. For that financial year CELPHARMA recorded a gross margin of € 635,609 and equity of € 1.9 million. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 1.9 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 242,673
Profit after tax over the fiscal year.
€ 150,000 paid out
62 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
1.2
Average over the fiscal year, from the social balance sheet.
€ 181,098
€ 150,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,608
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.4 million
€ 139,227 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 177,343
Supplier invoices still open on the last day of the fiscal year.
€ 25,517
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to CELPHARMA?
What happened at CELPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 242,673. filed late Source: NBB ↗
- New establishment in Elsene. KBO
- New establishment in Zaventem. KBO
- Start of the company according to the CBE. KBO
In short
Paid € 79,068 in corporate taxes since 2025.
On average € 529,700 of value added per employee in 2025.
Paid out € 150,000 in dividends to the owners in total.
A new publication or filing at CELPHARMA? We notify you, reason included.
Follow CELPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind CELPHARMA are Thomas Van Acker, Think BVA SRL, Antoine Carlhian, Gabriele Gavazzi and Laurent Ruessman. Thomas Van Acker is also behind THEVA CONSULTING. Think BVA SRL is also behind TEONIA and CEL CLINIC. Antoine Carlhian is also behind TEONIA.
Directors
According to the 2025 annual accounts
Gabriele Gavazzi
Director
Laurent Ruessman
administrateur
Establishments
Establishment units
Physical locations of this company
Louizalaan 503 box 9
1050 Elsene
Belgicastraat 9 box 13
1930 Zaventem
Active since 14 July 2025
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 8 companies are registered at this address.
All companies at this address →JOANNIDIS JEWELLERY
RODIPAX
LA PREVOYANCE DE BELGIQUE
CROSS ET CABLE
€ 91,082 revenue · 2025
LINGUERE
€ 14,512 gross margin · 2025
+3 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1025.475.981
- VAT number
- BE 1025.475.981
- Registered office
- Louizalaan 503 bus 9, 1050 Elsene
- Names & denominations
- CELPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 14 July 2025
- Peppol
- Active · Active since 3 Mar 2026
- Activities · NACE
Vervaardiging van parfums en toiletartikelen
Handelsbemiddeling in de groothandel in andere specifieke goederen
Activiteiten van reclamebureaus
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden